Harnessing Your Body's Own Chemistry to Treat Ovarian Cancer
August 04, 2011
Spread the Word to
Friends And Family
By Sharing this Article.
Researchers have discovered that a low dose of the opioid antagonist naltrexone (LDN) can have an extraordinarily potent antitumor effect on human ovarian cancer in tissue culture.
The discovery provides new insights into the pathogenesis and treatment of ovarian neoplasia, which is the 4th leading cause of cancer-related mortality among U.S. women. The strategy of using LDN therapy to repress cancer was first reported over 30 years ago. Naltrexone causes an elevation in your body's own opioids and opioid receptors.
"Blockade of opioid peptides from opioid receptors for a short time each day (4 to 6 hr) with LDN provides a sufficient window of time (18-20 hr) for the elevated levels of endogenous opioids and opioid receptors to interact and elicit a response: inhibition of cell proliferation. Thus, LDN acts as a decoy to upregulate native opioids and opioid receptors."
Stay Up-To-Date on the Latest Health News
If you haven't already, here's your chance to subscribe to the world's most popular newsletter! My FREE newsletter is instrumental in changing the lives of many people across the world. If you want to take control of your health then you won't want to miss out on this opportunity.
When you subscribe I guarantee:
- You'll be the first to hear about fast-breaking health news and hard-to-find tips for improving your emotional, physical, and spiritual well-being
- You'll save money because I'm committed to helping you stay healthy, so you won't need expensive prescription drugs or doctor's visits so often
- You'll get straight talk from me in plain English that shatters all the myths and misconceptions about health, aging, and fitness
Don't be left in the dark on breaking health news! Sign up for my daily newsletter today!